These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11818704)

  • 21. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group.
    Indridason OS; Quarles LD
    Kidney Int; 2000 Jan; 57(1):282-92. PubMed ID: 10620210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients.
    Borrego MJ; Martin-Malo A; Almaden Y; Rodriguez M; Aljama P; Felsenfeld AJ
    Am J Kidney Dis; 1999 Sep; 34(3):456-63. PubMed ID: 10469855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
    Park JH; Park KH; Cho S; Choi YS; Seo SK; Lee BS; Park HS
    Menopause; 2013 Jul; 20(7):747-53. PubMed ID: 23511701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
    Peng SJ; Yang CS; Ferng SH; Chen LY
    Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bio-intact parathyroid hormone and intact parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism receiving intravenous calcitriol therapy.
    Fujimori A; Sakai M; Yoshiya K; Shin J; Kim JI; Inaba Y; Miyamoto T; Inoue S; Fukagawa M
    Ther Apher Dial; 2004 Dec; 8(6):474-9. PubMed ID: 15663547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
    Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
    Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
    Kihara T; Ichikawa H; Morimoto H; Yano A; Akagi S; Nakao K; Kohmoto H; Wada J; Kumagai I; Makino H
    Nephron Clin Pract; 2004; 98(3):c93-100. PubMed ID: 15528944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcitriol oral pulse therapy in children with renal osteodystrophy.
    Cano F; Delucchi A; Wolff E; Rodriguez E; Fuentes A
    Pediatr Nephrol; 1995 Oct; 9(5):606-8. PubMed ID: 8580020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation.
    Torres A; García S; Gómez A; González A; Barrios Y; Concepción MT; Hernández D; García JJ; Checa MD; Lorenzo V; Salido E
    Kidney Int; 2004 Feb; 65(2):705-12. PubMed ID: 14717945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calcitriol per os once, twice or three times a week: effect of different schedules of administration in hemodialysis patients.
    Manni M; Calabria S; Dinnella A; D'Anello E; Mantella D; Sardella D; Sturniolo A; Splendiani G; Coen G
    Am J Nephrol; 2000; 20(6):443-7. PubMed ID: 11146310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
    Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
    Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidism.
    Katoh N; Nakayama M; Shigematsu T; Yamamoto H; Sano K; Saito I; Nakano H; Kasai K; Kubo H; Sakai S; Kawaguchi Y; Hosoya T
    Am J Kidney Dis; 2000 Mar; 35(3):465-8. PubMed ID: 10692272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
    Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
    Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
    Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
    Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis.
    Inanir A; Ozoran K; Tutkak H; Mermerci B
    J Int Med Res; 2004; 32(6):570-82. PubMed ID: 15587751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
    Moe S; Wazny LD; Martin JE
    Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Denosumab and Calcitriol on Severe Secondary Hyperparathyroidism in Dialysis Patients With Low Bone Mass.
    Chen CL; Chen NC; Liang HL; Hsu CY; Chou KJ; Fang HC; Lee PT
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2784-92. PubMed ID: 25955225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Skeletal scintigraph and some bone turnover markers in the diagnosis of renal osteodystrophy in hemodialysis patients].
    Bednarek-Skublewska A; Chrapko B; Ksiazek A
    Pol Arch Med Wewn; 2003 Sep; 110(3):943-50. PubMed ID: 14699686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
    Lee SH; Huang TS; Hsieh SJ
    Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.